# Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

> **NCT02433834** · PHASE2 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 248 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Glycopyrronium MDI
- **DRUG:** Serevent Diskus 50 μg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02433834
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-27
- **Primary completion:** 2016-03-26
- **Final completion:** 2016-03-26
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02433834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02433834, "Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02433834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*